Trials / Completed
CompletedNCT01036165
A Multicenter, Open-label, RebiSmart™ Autoinjector Ease of Use Study
A Twelve-week, Phase IIIb, Open-label, Single-arm, Multicenter Trial to Evaluate Ease of Use of an Electronic Autoinjector (RebiSmart™) for Self-injection in Subjects With Relapsing Multiple Sclerosis (RMS) Treated With Rebif® 44mcg Subcutaneously (sc) Three Times a Week (Tiw)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 103 (actual)
- Sponsor
- EMD Serono · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to test the RebiSmart™ for * ease of use * multiple domains related to subject's acceptability and satisfaction * reliability of the correct function for self-injection of Rebif® 44 mcg sc tiw in subjects with RMS.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | RebiSmart™ | The RebiSmart™ autoinjector contains Rebif® 132 mcg multidose cartridges for sc injection. |
Timeline
- Start date
- 2010-01-01
- Primary completion
- 2010-08-01
- Completion
- 2010-08-01
- First posted
- 2009-12-21
- Last updated
- 2013-08-08
- Results posted
- 2010-12-22
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01036165. Inclusion in this directory is not an endorsement.